About black diamond therapeutics inc - BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
BDTX At a Glance
Black Diamond Therapeutics, Inc.
245 First Street
Cambridge, Massachusetts 02142
| Phone | 1-617-252-0848 | Revenue | 70.00M | |
| Industry | Biotechnology | Net Income | 22.37M | |
| Sector | Health Technology | Employees | 21 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BDTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 6.253 |
| Price to Sales Ratio | 1.998 |
| Price to Book Ratio | 1.237 |
| Price to Cash Flow Ratio | 4.72 |
| Enterprise Value to EBITDA | 1.486 |
| Enterprise Value to Sales | 0.429 |
| Total Debt to Enterprise Value | 0.626 |
BDTX Efficiency
| Revenue/Employee | 3,333,333.333 |
| Income Per Employee | 1,065,095.238 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.527 |
BDTX Liquidity
| Current Ratio | 8.419 |
| Quick Ratio | 8.419 |
| Cash Ratio | 8.178 |
BDTX Profitability
| Gross Margin | 99.536 |
| Operating Margin | 28.386 |
| Pretax Margin | 31.953 |
| Net Margin | 31.953 |
| Return on Assets | 16.839 |
| Return on Equity | 22.882 |
| Return on Total Capital | 17.075 |
| Return on Invested Capital | 19.505 |
BDTX Capital Structure
| Total Debt to Total Equity | 16.737 |
| Total Debt to Total Capital | 14.338 |
| Total Debt to Total Assets | 13.133 |
| Long-Term Debt to Equity | 13.428 |
| Long-Term Debt to Total Capital | 11.503 |